ELF2

Across TCGA pan-cancer cohorts, ELF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELF2 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ELF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and COAD are the cancer types where ELF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.086	0.751	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.915	0.305	.018	18	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
LUAD	OS	Median	All	0.237	0.787	.014	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELF2–HNSC (OS)

Open the HNSC breakdown →